Published in Immunity on August 01, 2001
A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia | NCT01142011
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol (2002) 6.85
PI3 kinase signals BCR-dependent mature B cell survival. Cell (2009) 4.43
Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest (2002) 4.14
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum (2009) 3.34
The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology (2005) 3.18
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2003) 2.82
NF-κB in immunobiology. Cell Res (2011) 2.61
Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A (2004) 2.57
Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood (2011) 2.47
Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity (2007) 2.17
APRIL modulates B and T cell immunity. J Clin Invest (2002) 2.07
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood (2012) 2.07
Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest (2006) 2.05
The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. Immunity (2013) 2.02
The B Cell-Stimulatory Cytokines BLyS and APRIL Are Elevated in Human Periodontitis and Are Required for B Cell-Dependent Bone Loss in Experimental Murine Periodontitis. J Immunol (2015) 2.02
BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism. J Exp Med (2006) 1.93
BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A (2008) 1.88
Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med (2003) 1.85
BLyS and APRIL in rheumatoid arthritis. J Clin Invest (2005) 1.75
Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood (2007) 1.64
Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med (2001) 1.57
The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol (2012) 1.49
Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol (2006) 1.43
Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum (2010) 1.37
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther (2006) 1.36
BAFF activates Akt and Erk through BAFF-R in an IKK1-dependent manner in primary mouse B cells. Proc Natl Acad Sci U S A (2008) 1.29
APRIL-deficient mice have normal immune system development. Mol Cell Biol (2004) 1.29
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet (2013) 1.29
B cells and humoral immunity in atherosclerosis. Circ Res (2014) 1.25
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci U S A (2004) 1.21
DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem (2003) 1.20
Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol (2010) 1.19
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther (2010) 1.18
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. Br J Cancer (2009) 1.17
Human endometriosis is associated with plasma cells and overexpression of B lymphocyte stimulator. Proc Natl Acad Sci U S A (2007) 1.14
The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis (2006) 1.11
Perspectives on common variable immune deficiency. Ann N Y Acad Sci (2011) 1.09
Selective activation of TACI by syndecan-2. Blood (2005) 1.09
B-cell targeted therapeutics in clinical development. Arthritis Res Ther (2013) 1.09
Mutational analysis of human BAFF receptor TNFRSF13C (BAFF-R) in patients with common variable immunodeficiency. J Clin Immunol (2005) 1.09
Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord (2010) 1.08
High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency. Clin Immunol (2007) 1.08
Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells. PLoS One (2009) 1.06
Ras activation of Erk restores impaired tonic BCR signaling and rescues immature B cell differentiation. J Exp Med (2010) 1.05
Analysis of an ethylnitrosourea-generated mouse mutation defines a cell intrinsic role of nuclear factor kappaB2 in regulating circulating B cell numbers. J Exp Med (2002) 1.04
Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann Rheum Dis (2003) 1.00
BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling. J Immunol (2010) 0.99
The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int (2007) 0.98
B cell receptor-mediated sustained c-Rel activation facilitates late transitional B cell survival through control of B cell activating factor receptor and NF-kappaB2. J Immunol (2009) 0.97
BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One (2011) 0.97
Immune opsonins modulate BLyS/BAFF release in a receptor-specific fashion. J Immunol (2008) 0.96
Expression of BAFF-R (BR 3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody. Virchows Arch (2005) 0.96
Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther (2008) 0.95
Enhanced B cell expansion, survival, and humoral responses by targeting death receptor 6. J Exp Med (2003) 0.95
Anticytokine therapies in systemic lupus erythematosus. Immunotherapy (2010) 0.94
A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. J Exp Med (2010) 0.94
The antigen presenting cells instruct plasma cell differentiation. Front Immunol (2014) 0.94
BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses. J Immunol (2012) 0.93
TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathog (2016) 0.92
Multiple regulatory mechanisms control B-1 B cell activation. Front Immunol (2012) 0.92
Expression of B-cell activating factor enhances protective immunity of a vaccine against Pseudomonas aeruginosa. Infect Immun (2009) 0.91
Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice. Immunology (2006) 0.91
Non-Canonical NF-κB Signaling Initiated by BAFF Influences B Cell Biology at Multiple Junctures. Front Immunol (2014) 0.91
Specific in vivo deletion of B-cell subpopulations expressing human immunoglobulins by the B-cell superantigen protein L. Infect Immun (2004) 0.89
Requirement for BAFF and APRIL during B cell development in GALT. J Immunol (2010) 0.89
Update on Targets of Biologic Therapies for Rheumatoid Arthritis. Curr Rheumatol Rev (2008) 0.89
A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathol (2006) 0.89
Synovial tissues concentrate secreted APRIL. Arthritis Res Ther (2009) 0.88
The TNF family member APRIL promotes colorectal tumorigenesis. Cell Death Differ (2012) 0.88
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol (2007) 0.87
The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res Ther (2004) 0.87
Coupling between B cell receptor and phospholipase C-gamma2 is essential for mature B cell development. J Exp Med (2003) 0.87
The receptor tyrosine kinase MerTK regulates dendritic cell production of BAFF. Autoimmunity (2009) 0.87
Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis Rheum (2013) 0.87
BAFF overexpression promotes anti-dsDNA B-cell maturation and antibody secretion. Cell Immunol (2009) 0.87
Human B cell defects in perspective. Immunol Res (2012) 0.86
Analysis of the regulatory role of BAFF in controlling the expression of CD21 and CD23. Mol Immunol (2006) 0.86
Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma. Am J Hematol (2009) 0.86
SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther (2003) 0.86
Therapeutic effects of TACI-Ig on rat with adjuvant arthritis. Clin Exp Immunol (2010) 0.86
Regulation of B cell activating factor (BAFF) receptor expression by NF-ΚB signaling in rheumatoid arthritis B cells. Exp Mol Med (2011) 0.85
The buzz about BAFF. J Clin Invest (2002) 0.85
B-cell-activating factor inhibits CD20-mediated and B-cell receptor-mediated apoptosis in human B cells. Immunology (2008) 0.85
Antigen and cytokine receptor signals guide the development of the naïve mature B cell repertoire. Immunol Res (2013) 0.85
Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis. Clin Exp Immunol (2014) 0.84
Impairment of Mature B Cell Maintenance upon Combined Deletion of the Alternative NF-κB Transcription Factors RELB and NF-κB2 in B Cells. J Immunol (2016) 0.84
The adaptor molecule Act1 regulates BAFF responsiveness and self-reactive B cell selection during transitional B cell maturation. J Immunol (2010) 0.83
The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity. J Exp Med (2014) 0.83
B cells as effectors and regulators of sex-biased arthritis. Autoimmunity (2012) 0.82
Human IgA-inducing protein from dendritic cells induces IgA production by naive IgD+ B cells. J Immunol (2009) 0.82
Nogo-receptors NgR1 and NgR2 do not mediate regulation of CD4 T helper responses and CNS repair in experimental autoimmune encephalomyelitis. PLoS One (2011) 0.82
TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice. Oral Dis (2011) 0.82
B-cell-activating factor and autoimmune myasthenia gravis. Autoimmune Dis (2011) 0.82
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions. Front Immunol (2015) 0.81
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci (2012) 0.81
Somatically diversified and proliferating transitional B cells: implications for peripheral B cell homeostasis. J Immunol (2011) 0.81
Efficient B cell responses to Borrelia hermsii infection depend on BAFF and BAFFR but not TACI. Infect Immun (2013) 0.81
APRIL mediates peritoneal B-1 cell homeostasis. Immunol Lett (2014) 0.80
Targeting dendritic cell function during systemic autoimmunity to restore tolerance. Int J Mol Sci (2014) 0.80
Observational study of effect of patient centredness and positive approach on outcomes of general practice consultations. BMJ (2001) 8.76
Kidney transplantation under FK 506. JAMA (1990) 7.45
Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA (1991) 7.35
Performance indicators for primary care groups: an evidence based approach. BMJ (1998) 6.97
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54
Preferences of patients for patient centred approach to consultation in primary care: observational study. BMJ (2001) 6.17
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
RHABDOMYOSARCOMA OF THE URINARY BLADDER. Ann Surg (1939) 5.53
The chorio-allantoic membrane of the developing chick as a medium for the cultivation and histopathologic study of pathogenic fungi. Am J Pathol (1941) 4.64
Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science (1997) 4.23
23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet (2000) 4.23
Gain of function mutations in p53. Nat Genet (1993) 4.19
Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. BMJ (2001) 4.18
Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A (1997) 4.10
The Chorioallantoic Membrane of Chick Embryos and Its Response to Inoculation with Some Mycobacteria. Am J Pathol (1942) 4.02
Prevalence of Alzheimer's disease and other dementias in rural India: the Indo-US study. Neurology (1998) 3.82
Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg (1996) 3.76
Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics (2000) 3.48
The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol Cell Biol (1986) 3.36
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut (2005) 3.32
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Growth factor control of skeletal muscle differentiation: commitment to terminal differentiation occurs in G1 phase and is repressed by fibroblast growth factor. J Cell Biol (1987) 3.28
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene (2010) 3.05
A study of clients returning for counseling after HIV testing: implications for improving rates of return. Public Health Rep (1993) 3.01
Panfungal PCR assay for detection of fungal infection in human blood specimens. J Clin Microbiol (1998) 2.92
Multiple adenovirus serotypes use alpha v integrins for infection. J Virol (1994) 2.86
Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J Immunol (2001) 2.85
High-efficiency transformation of Chlamydomonas reinhardtii by electroporation. Genetics (1998) 2.66
V(D)J recombinase activity in a subset of germinal center B lymphocytes. Science (1997) 2.58
Relationship between trauma center volume and outcomes. JAMA (2001) 2.56
Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch Intern Med (2001) 2.51
Transgenic mice containing a 248-kb yeast artificial chromosome carrying the human beta-globin locus display proper developmental control of human globin genes. Proc Natl Acad Sci U S A (1993) 2.46
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol (2002) 2.46
Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell (2001) 2.45
CAISSON DISEASE WITH SPECIAL REFERENCE TO THE BONES AND JOINTS: REPORT OF TWO CASES. Ann Surg (1940) 2.44
Dipsticks and diagnostic algorithms in urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort and qualitative study. Health Technol Assess (2009) 2.36
Randomised controlled trial of self management leaflets and booklets for minor illness provided by post. BMJ (2001) 2.35
GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney. Neuron (1998) 2.34
Regulation of transcription by cyclic AMP-dependent protein kinase. Proc Natl Acad Sci U S A (1989) 2.33
Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucleic Acids Res (1995) 2.33
Overnight calls in primary care: randomised controlled trial of management using nurse telephone consultation. BMJ (1999) 2.32
Tuberculosis among foreign-born persons in the United States, 1993-1998. JAMA (2000) 2.31
The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol (1999) 2.28
Validation study of a diary for use in acute lower respiratory tract infection. Fam Pract (2001) 2.24
Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. Am J Physiol Gastrointest Liver Physiol (2001) 2.23
Importance of lead selection in QT interval measurement. Am J Cardiol (1988) 2.23
Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet (2000) 2.21
Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Edinburgh Heterosexual Transmission Study Group. Lancet (1996) 2.20
Myogenic differentiation in permanent clonal mouse myoblast cell lines: regulation by macromolecular growth factors in the culture medium. Dev Biol (1981) 2.20
Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther (2001) 2.19
Diagnosis and management of Cushing's syndrome. Lancet (1999) 2.17
Clinical governance in primary care groups: the feasibility of deriving evidence-based performance indicators. Qual Health Care (2000) 2.16
Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell (1994) 2.15
Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf) (1997) 2.14
Phosphorylation and activation of cAMP-dependent protein kinase by phosphoinositide-dependent protein kinase. Proc Natl Acad Sci U S A (1998) 2.09
The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev (1998) 2.06
Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer (1984) 2.05
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol (2007) 2.03
Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res (2001) 2.00
Cost analysis of nurse telephone consultation in out of hours primary care: evidence from a randomised controlled trial. BMJ (2000) 1.99
Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. Eur Arch Psychiatry Clin Neurosci (1992) 1.96
Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. J Exp Med (1996) 1.93
Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med (1994) 1.93
Visualizing synapse formation in arborizing optic axons in vivo: dynamics and modulation by BDNF. Nat Neurosci (2001) 1.93
The beta-globin stage selector element factor is erythroid-specific promoter/enhancer binding protein NF-E4. Genes Dev (1989) 1.90
Control of mouse myoblast commitment to terminal differentiation by mitogens. J Supramol Struct (1980) 1.89
Type IV pilus biogenesis and motility in the cyanobacterium Synechocystis sp. PCC6803. Mol Microbiol (2000) 1.87
The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus. An application of the Bradford Hill criteria. Sex Transm Dis (1997) 1.86
Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. N Engl J Med (1977) 1.85
Sac1, a putative regulator that is critical for survival of Chlamydomonas reinhardtii during sulfur deprivation. EMBO J (1996) 1.83
POLYAMINES, RNA SYNTHESIS, AND STREPTOMYCIN LETHALITY IN A RELAXED MUTANT OF E. coli STRAIN 15 TAU. Proc Natl Acad Sci U S A (1967) 1.82
Demonstration of cell-surface antigens on chemically induced tumors. Ann N Y Acad Sci (1971) 1.78
Psychosocial, lifestyle, and health status variables in predicting high attendance among adults. Br J Gen Pract (2001) 1.76
Ultrasensitive detection and characterization of biomolecules using superchiral fields. Nat Nanotechnol (2010) 1.76
Use of yeast artificial chromosomes (YACs) in studies of mammalian development: production of beta-globin locus YAC mice carrying human globin developmental mutants. Proc Natl Acad Sci U S A (1995) 1.74
Effect of deletion of 5'HS3 or 5'HS2 of the human beta-globin locus control region on the developmental regulation of globin gene expression in beta-globin locus yeast artificial chromosome transgenic mice. Proc Natl Acad Sci U S A (1996) 1.74
Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem (2001) 1.73
THE CHORIO-ALLANTOIC MEMBRANE OF THE DEVELOPING CHICK AS A MEDIUM FOR THE CULTIVATION AND HISTOPATHOLOGIC STUDY OF PATHOGENIC FUNGI. Science (1939) 1.71
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer (2009) 1.69
Centers for Disease Control. Enteroviral disease in the United States, 1970-1979. J Infect Dis (1982) 1.69
Developmental specificity of the interaction between the locus control region and embryonic or fetal globin genes in transgenic mice with an HS3 core deletion. Mol Cell Biol (1998) 1.67
Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum (2001) 1.67
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol (2010) 1.65
Nucleotide sequence of a chromosomal mercury resistance determinant from a Bacillus sp. with broad-spectrum mercury resistance. J Bacteriol (1989) 1.64